查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092178

醫療相關感染疾病診斷市場－2026-2032年全球市場預測

Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫療保健相關感染疾病診斷市場將成長至 497.7 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年 2025 276.6億美元
預計年份：2026年 298.2億美元
預測年份 2032 497.7億美元
複合年成長率 (%) 8.75%

醫療相關感染疾病)的診斷對於病人安全、合理使用抗生素、預防感染以及提升醫院品質至關重要。包括導尿管相關尿道感染、中央靜脈導管相關血流感染疾病、人工呼吸器相關性肺炎、手術部位感染疾病、困難梭狀桿菌感染疾病以及多重抗藥性細菌感染疾病的​​ HAI，仍是急診醫院、長期照護機構、門診手術中心和診斷檢查室面臨的挑戰。經營團隊重點正從被動檢測轉向快速、整合、基於風險的診斷流程，以便在診療過程早期識別病原體、抗藥性標記和感染風險。這種需求的產生源於 HAI 監測要求的加強、分子診斷技術的日益普及、人們對抗生素抗藥性的認知不斷提高，以及在加護病房、腫瘤科、移植病房和新生兒護理等高風險環境中快速做出臨床決策的需求。核心技術包括基於培養的微生物學、免疫檢測、核酸增幅檢查、症候群特異性檢測、質譜分析、定序和數位監測平台。其最大提案在於加快獲得可操作結果的速度，改善隔離決策，支持標靶抗生素治療，並加強對感染控制標準的遵守。對於相關人員，成功的關鍵在於提供證據，證明在臨床準確性、工作流程相容性、成本效益、與醫院資訊系統的互通性以及病患預後和感染預防效果方面均有可衡量的改進。

診斷領域的變革性變化

醫療相關感染疾病）診斷領域正經歷結構性變革，其驅動力來自更快速的檢測方法、分散化的獲取途徑以及診斷與感染預防項目之間更緊密的整合。儘管傳統的培養方法對於病原體分離、藥敏試驗和流行病學調查仍然至關重要，但醫院擴大使用分子和快速表現型工具來縮短病原體鑑定和抗藥性檢測所需的時間。基於症候群的檢測有助於臨床醫生評估可能由多種細菌、病毒或真菌引起的複雜感染疾病，而定序支持集體爆發調查和菌株層面的監測。另一個顯著的轉變是從檢查室檢測轉向患者現場檢測和即時檢測（POC​​）工作流程，尤其是在需要快速分離病原體、隊列管理或強化治療決策的特定應用場景中。此外，隨著醫療系統努力確保“在正確的時間為正確的患者進行正確的檢測”，最大限度地減少假陽性、不必要的治療和可避免的成本，診斷管理正成為一個至關重要的問題。監管預期、醫院認證壓力以及感染指標的公開報告，都在推動檢驗、可重複且可互通的診斷解決方案的需求。同時，抗生素抗藥性問題也進一步凸顯了檢測抗藥性基因、整合區域抗生素敏感性譜以及快速獲取藥敏資訊的重要性。因此，市場格局正朝著整合了檢查室卓越性、即時數據交換和感染控制資訊的綜合診斷生態系統轉變。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過增強檢測選擇、結果解讀、監測和操作決策，為整個醫療相關感染疾病診斷流程增添了智慧層面。在臨床微生物檢查室中，AI 驅動的影像分析可輔助快速篩檢培養皿、革蘭氏染色結果解讀和菌落鑑定。機器學習模型有助於確定檢體優先級，並識別需要專家審核的異常抗藥性模式。在醫院感染預防方面，AI 整合了檢測結果、入院數據、醫療設備使用情況、抗生素給藥情況、床位調動情況和電子健康記錄信息，以幫助識別叢集、預測集體爆發風險並促進早期療育。自然語言處理可以從臨床記錄和手術報告中提取感染疾病相關訊息，從而提高病例檢出率和監測覆蓋率。 AI 還透過將診斷結果與患者特定因素和區域抗藥性趨勢相關聯，支持更有針對性的治療建議並促進合理使用抗生素。這些影響是累積的，隨著 AI 整合到從分析前分診到分析品管、分析後解讀和人群監控的整個工作流程中，其價值將不斷提升。然而，透明的檢驗、可解釋性、網路安全措施、偏見監測以及與臨床管治的協調一致，對於人工智慧的實施至關重要。醫療機構正在優先採用能夠與現有實驗室資訊系統和電子健康記錄整合、產生可審計建議並帶來切實益處的人工智慧工具，例如更快地報告檢測結果、提高集體爆發檢測的準確性、減少不必要的檢測以及合理使用抗生素。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

在亞太地區，大規模醫院網路、不斷成長的手術量以及人們對抗生素抗藥性的日益關注，推動了對快速感染檢測的需求，並促進了快速診斷方法的廣泛應用。中國、印度、日本、韓國和澳洲正在投資檢查室，這得益於完善的醫院報告系統、合理的抗生素使用方案、分子檢測的引入以及診斷數據與電子健康記錄的深度整合。在拉丁美洲，公共衛生檢查室的改善和醫院感染控制工作的加強，提高了診斷服務的可近性。巴西和墨西哥正致力於擴大檢測能力，但資源差異和抗菌素抗藥性監測仍面臨挑戰。歐洲的特點是擁有成熟的感染預防框架、跨境抗菌素抗藥性監測以及積極採用品質保證的檢測方法，歐洲的醫療保健系統也日益重視標準化監測和診斷管理。在中東，醫院基礎設施、基於認證系統的感染控制以及檢查室自動化方面都取得了進展。尤其是在海灣合作理事會（GCC）成員國的醫療衛生系統中，三級醫療和醫療旅遊的擴張正在推動對快速可靠診斷的需求。非洲面臨感染疾病負擔沉重和檢測能力不平衡的雙重挑戰，但透過投資抗菌素抗藥性計畫、感染預防計畫、分子檢測、參考檢查室和集體爆發監測，該地區正在取得區域性進展。所有區域的通用成長要素包括強制性患者安全措施、抑制抗菌素抗藥性、擴大外科手術和重症監護，以及醫療機構對即時診斷資訊的需求。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，隨著區域內公立和私立醫療衛生系統不斷擴大醫院基礎設施、加強感染預防計畫並應對抗生素抗藥性威脅，醫療相關感染的診斷已成為一項優先事項。海灣合作理事會（GCC）國家正通過醫院認證體系、對數位醫療的投資、先進的檢查室自動化以及將診斷與品質改進和患者安全目標相結合的抗菌藥物管理舉措，取得快速進展。歐盟受益於協調的監測系統、抗生素抗藥性監測、醫療設備法規和跨境公共衛生合作，將標準化、資料互通性和診斷品質作為核心優先事項。金磚國家是一個多元化但又極具影響力的群體，其大規模的患者群體、不斷擴展的三級醫療服務、國家層面的抗生素抗藥性應對措施以及國內診斷能力的提升，使得快速且擴充性的檢測方法變得日益重要。七國集團（G7）國家普遍擁有較高的診斷技術普及率、強大的檢查室網路和成熟的抗菌藥物管理政策，並持續致力於減少醫院感染、縮短檢測結果報告時間以及將診斷整合到數位化醫療路徑中。北約成員國擁有眾多高度重視先進生物防禦、緊急準備和感染疾病監測的醫療衛生系統，因此對能夠應對常規醫院感染、疫情爆發和突發事件的彈性診斷基礎設施有著迫切的需求。在這一群體中，最大的商業機會在於協調監測系統、實現採購流程現代化、培養檢查室人才、完善診斷管理以及檢驗可在複雜醫療衛生系統中部署的成熟技術。

主要醫療保健市場的關鍵國別洞察

美國擁有高度發展的醫療相關感染疾病監測系統，重點關注醫院報告、合理使用抗生素以及在高風險醫療環境中進行快速分子診斷。加拿大則著重於病人安全、抗生素抗藥性監測以及省級醫療系統內協調一致的感染預防措施。墨西哥正在擴展其診斷能力，以應對醫院網路在感染控制和抗生素抗藥性監測方面的需求和挑戰。巴西擁有大規模的醫療體系、標準化的檢查室以及持續進行的抗生素抗藥性應對措施，因此是拉丁美洲醫院感染診斷的主要市場。英國強調全國範圍的監測、診斷管理和跨醫院感染預防標準，而德國則將先進的檢查室基礎設施與強大的微生物學和醫院品管系統相結合。法國繼續優先考慮抗生素管理和感染監測，並輔以系統化的醫療品質計劃；俄羅斯正在其大規模的醫院網路中提升診斷能力，同時努力解決檢查室獲取方面的區域差異。義大利和西班牙保持強大的醫院微生物學能力和感染控制計劃，並繼續專注於手術部位感染、多重抗藥性細菌和艱難梭菌感染的管理。在中國，隨著三級醫院不斷提升其先進的檢測能力，醫院現代化、分子診斷和抗菌藥物抗藥性防治領域正投入大量資金。印度正透過全國性的抗菌藥物抗藥性防治運動、不斷擴大的私立醫院網路以及分子檢測的廣泛應用，加強感染預防和診斷的可及性。日本擁有成熟的診斷體系，配備先進的醫院檢查室，滿足老齡化社會的醫療保健需求，並制定了嚴格的品質標準。澳洲強調全國範圍內的抗菌藥物抗藥性監測、感染預防指南和高品質的檢測網路，而韓國則結合了先進的數位醫療基礎設施、醫院認證體係以及積極應用分子診斷技術。儘管這些國家的實施模式因報銷制度、檢查室成熟度、人力資源和法律規範的不同而有所差異，但它們通用迫切需要更快、更準確、更實用的診斷方法來降低醫療相關感染的風險。

為行業領導者提供的實用建議

行業領導者應優先考慮能夠平衡快速診斷與感染預防、合理使用抗生素以及提高醫院工作流程效率的解決方案。產品策略應著重於經臨床驗證的檢測方法，這些方法能夠在影響治療、隔離和醫療設備管理決策的時限內提供可操作的病原體鑑定和抗藥性資訊。開發人員應增強與實驗室資訊系統、電子健康記錄、監測平台和合理使用抗生素儀錶板的互通性，以確保檢驗結果可用於臨床實踐。銷售團隊應建立以患者預後、縮短最佳治療時間、提高疫情檢測能力、減少不必要的抗生素暴露以及提高營運效率為重點的證據包，而不是僅依賴分析性能方面的聲明。各機構還應透過向臨床醫生、微生物學家、藥劑師和感染控制負責人提供清晰的使用指南、結果解讀指導和培訓來支持診斷管理。區域策略應考慮到報銷制度、監管要求、檢查室基礎設施和人員配置結構的差異，並開發可擴展的模式，以適應高通量中心檢查室和分散式醫療機構的需求。人工智慧解決方案的實施應遵循透明的檢驗、網路安全措施和臨床管治框架。與醫院、公共衛生組織、學術機構和參考實驗室的合作能夠加速在真實臨床環境中的檢驗和部署。最重要的是，產業領導者應將醫療相關感染疾病診斷定位為保障病患安全和對抗抗生素抗藥性的產品類型。

調查方法

本執行摘要基於系統性的二手研究途徑，利用了檢驗的公共衛生、臨床、監管和產業相關資訊來源。分析採用了來自醫院感染預防指南、抗菌藥物抗藥性計畫、品質報告框架、同行評審的臨床文獻、公共衛生監測計畫、監管出版刊物和臨床實驗室醫學標準的證據。調查方法強調“三角測量”，即交叉引用多個可靠資訊來源，以識別診斷方法應用、技術進步、區域優先事項和醫療保健系統需求方面的一致主題。定性評估用於評估培養、分子免疫檢測、免疫測定、定序、質譜分析、數位監測和人工智慧驅動的決策支援在管理醫療相關感染中的作用。透過仔細檢視醫療保健基礎設施的成熟度、感染預防優先事項、抗菌藥物抗藥性措施、檢查室能力和數位健康準備情況，得出區域、群體和國家層面的見解。本分析有意排除市場規模、市場佔有率和預測，而是著重於資料支持的產業趨勢、臨床因素、法規環境和策略意義。關鍵字和術語的選擇與醫療保健相關感染疾病診斷、醫院感染檢測、抗生素抗藥性診斷、感染預防、分子診斷、診斷管理和臨床微生物學的工作流程一致，同時確保準確性和可讀性。

結論

醫療相關感染疾病(HAI) 的診斷正邁入一個更整合、數據驅動且更具臨床指導意義的時代。醫療系統面臨的核心挑戰不再只是檢測病原體，而是要足夠快速地檢測出病原體，以便指導隔離、治療、集體爆發控制和合理使用抗生素等決策。快速分子診斷、先進的微生物學工作流程、定序、數位化監測和人工智慧正在重塑醫院識別和管理感染疾病 的方式。在強制感染預防、檢查室現代化和抗抗生素抗藥性措施推動發展的地區，這種趨勢最為強勁，但無論成熟的醫療系統還是新興的醫療系統，對可靠診斷的需求都是普遍存在的。未來的競爭力將取決於臨床有效性、工作流程整合、經濟性、互通性以及診斷工具能夠改善病患安全結果的證據。能夠將精準檢驗與合理使用、監測和即時決策支援相結合的機構，將更有能力應對日益嚴重的感染疾病和多重抗藥性細菌感染問題。在這種環境下，診斷技術發揮著支撐現代醫學品質的策略支柱作用，能夠實現更早的干預、更有效地利用資源，並更好地保護患者、臨床醫生和醫療保健系統。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：醫療相關感染疾病診斷市場：依檢測方法分類

  • 免疫測量
    • 化學冷光免疫檢測
    • ELISA
    • 橫向流動化驗
  • 微生物學
    • 培養方法
      • 需氧培養
      • 厭氧培養
    • 顯微鏡
    • 敏感性測試
  • 分子診斷
    • 等溫擴增
    • PCR
    • 定序

第8章：醫療保健相關感染疾病診斷市場：以病原體類型分類

  • 細菌
    • 困難梭狀芽孢桿菌
    • 大腸桿菌
    • 銅綠假單胞菌
    • 金黃色葡萄球菌
  • 真菌
    • 麴菌屬
    • 念珠菌屬
    • 新型隱球菌
  • 寄生
    • 瘧疾原蟲
    • 弓形蟲
  • 病毒性的
    • 新冠病毒
    • 流感病毒
    • 諾羅病毒
    • 呼吸道融合細胞病毒

第9章：醫療保健相關感染疾病診斷市場：依樣本類型分類

  • 血
    • 血清
    • 全血
  • 腦脊髓液
  • 呼吸系統
    • 支氣管肺泡灌洗
    • 鼻咽拭子
    • 痰
  • 尿
    • 透過導尿管收集的尿液
    • 中段尿
  • 傷口拭子
    • 深層組織檢體
    • 表面拭子

第10章：醫療保健相關感染疾病診斷市場：以最終用戶分類

  • 診斷檢查室
    • 獨立檢測實驗室
    • 參考實驗室
  • 醫院
    • 臨床病理檢查室
    • 微生物檢查室
  • 照護現場
    • 診所
    • 急診室
    • 長期照護機構

第11章：醫療保健相關感染疾病診斷市場：按應用分類

  • 篩檢
  • 診斷
  • 監測
  • 監視

第12章：醫療保健相關感染疾病診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：醫療保健相關感染疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：醫療保健相關感染疾病診斷市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Accelerate Diagnostics Inc
  • Agilent Technologies Inc
  • Bio-Rad Laboratories Inc
  • bioMerieux SA
  • Co-Diagnostics Inc
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Genetic Signatures Ltd
  • Grifols SA
  • Hologic Inc
  • Illumina Inc
  • Labcorp Holdings Inc
  • Luminex Corporation
  • Merck KGaA
  • Meridian Bioscience Inc
  • Natera Inc
  • OpGen Inc
  • OraSure Technologies Inc
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Revvity Inc
  • SD Biosensor Inc
  • Seegene Inc
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc
  • Trinity Biotech PLC
Product Code: MRR-8760467AA424

The Healthcare-associated Infectious Disease Diagnostics Market is projected to grow by USD 49.77 billion at a CAGR of 8.75% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.66 billion
Estimated Year [2026] USD 29.82 billion
Forecast Year [2032] USD 49.77 billion
CAGR (%) 8.75%

Healthcare-associated infectious disease diagnostics are becoming central to patient safety, antimicrobial stewardship, infection prevention, and hospital quality performance. Healthcare-associated infections, including catheter-associated urinary tract infections, central line-associated bloodstream infections, ventilator-associated pneumonia, surgical site infections, Clostridioides difficile infection, and multidrug-resistant organism transmission, continue to challenge acute care hospitals, long-term care facilities, ambulatory surgery centers, and diagnostic laboratories. The executive priority is shifting from reactive testing to rapid, integrated, and risk-based diagnostic workflows that identify pathogens, resistance markers, and transmission risks earlier in the care pathway. Demand is being shaped by rising hospital-acquired infection surveillance requirements, expanding molecular diagnostics adoption, increased awareness of antimicrobial resistance, and the need for faster clinical decisions in high-risk settings such as intensive care units, oncology wards, transplant units, and neonatal care. Core technologies include culture-based microbiology, immunoassays, nucleic acid amplification tests, syndromic panels, mass spectrometry, sequencing, and digital surveillance platforms. The strongest value proposition lies in reducing time to actionable results, improving isolation decisions, supporting targeted antimicrobial therapy, and strengthening compliance with infection control standards. For industry stakeholders, success depends on clinical accuracy, workflow compatibility, cost-effectiveness, interoperability with hospital information systems, and evidence demonstrating measurable improvements in patient outcomes and infection prevention performance.

Transformative Shifts in the Diagnostic Landscape

The healthcare-associated infectious disease diagnostics landscape is undergoing a structural transformation driven by faster testing modalities, decentralized access, and stronger links between diagnostics and infection prevention programs. Traditional culture remains essential for organism recovery, susceptibility testing, and epidemiological investigation, but hospitals are increasingly complementing it with molecular assays and rapid phenotypic tools to shorten time to pathogen identification and resistance detection. Syndromic testing is helping clinicians evaluate complex infections where multiple bacterial, viral, or fungal causes may be present, while sequencing is supporting outbreak investigation and strain-level surveillance. Another major shift is the movement from laboratory-only testing toward near-patient and point-of-care workflows for selected use cases, particularly where rapid isolation, cohorting, or treatment escalation decisions are needed. Diagnostic stewardship is also becoming a defining theme, as healthcare systems seek to ensure the right test is used for the right patient at the right time, minimizing false positives, unnecessary treatment, and avoidable costs. Regulatory expectations, hospital accreditation pressures, and public reporting of infection indicators are reinforcing demand for validated, reproducible, and interoperable diagnostic solutions. At the same time, antimicrobial resistance is elevating the importance of resistance gene detection, local antibiogram integration, and faster susceptibility insights. The market environment is therefore moving toward integrated diagnostic ecosystems that combine laboratory excellence, real-time data exchange, and infection control intelligence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding a cumulative layer of intelligence across healthcare-associated infectious disease diagnostics by enhancing test selection, result interpretation, surveillance, and operational decision-making. In clinical microbiology laboratories, AI-enabled image analysis can support faster screening of culture plates, Gram stain interpretation, and colony recognition, while machine learning models can help prioritize specimens or flag unusual resistance patterns for expert review. In hospital infection prevention, AI can combine laboratory results, admission data, device utilization, antibiotic exposure, bed movement, and electronic health record signals to identify clusters, predict outbreak risk, and support early intervention. Natural language processing can extract infection-relevant information from clinical notes and operative reports, improving case detection and surveillance completeness. AI also strengthens antimicrobial stewardship by linking diagnostic outputs with patient-specific factors and local resistance trends to support more targeted therapy recommendations. The impact is cumulative because value increases when AI is embedded across the entire workflow: pre-analytical triage, analytical quality control, post-analytical interpretation, and population-level surveillance. However, adoption depends on transparent validation, explainability, cybersecurity safeguards, bias monitoring, and alignment with clinical governance. Healthcare organizations are prioritizing AI tools that integrate with existing laboratory information systems and electronic health records, generate auditable recommendations, and demonstrate practical benefits such as shorter turnaround times, improved outbreak detection, reduced unnecessary testing, and better antimicrobial utilization.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

Asia-Pacific is witnessing expanding use of rapid diagnostics as large hospital networks, growing surgical volumes, and rising awareness of antimicrobial resistance increase the need for faster infection detection, with China, India, Japan, South Korea, and Australia investing in laboratory modernization and surveillance capacity. North America remains highly advanced in healthcare-associated infection monitoring, supported by established hospital reporting systems, antimicrobial stewardship programs, molecular testing adoption, and strong integration of diagnostic data into electronic health records. Latin America is strengthening diagnostic access through public health laboratory improvements and hospital infection control initiatives, with Brazil and Mexico emphasizing capacity expansion amid persistent challenges related to resource variability and antimicrobial resistance surveillance. Europe is characterized by mature infection prevention frameworks, cross-border antimicrobial resistance monitoring, and strong uptake of quality-assured laboratory testing, with European health systems placing increasing emphasis on standardized surveillance and diagnostic stewardship. The Middle East is advancing hospital infrastructure, accreditation-led infection control, and laboratory automation, particularly in GCC health systems where tertiary care expansion and medical tourism support demand for rapid and reliable diagnostics. Africa faces the dual challenge of high infectious disease burden and uneven laboratory capacity, but regional progress is visible through antimicrobial resistance action plans, infection prevention programs, and investments in molecular testing, reference laboratories, and outbreak surveillance. Across all regions, the common growth drivers are patient safety mandates, antimicrobial resistance containment, surgical and intensive care expansion, and the need for real-time diagnostic intelligence in healthcare facilities.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are prioritizing healthcare-associated infection diagnostics as regional health systems expand hospital infrastructure, strengthen infection prevention programs, and respond to antimicrobial resistance threats across both public and private care settings. The GCC is advancing rapidly through hospital accreditation, digital health investment, advanced laboratory automation, and stewardship initiatives that align diagnostics with quality improvement and patient safety objectives. The European Union benefits from coordinated surveillance structures, antimicrobial resistance monitoring, medical device regulation, and cross-country public health collaboration, making standardization, data interoperability, and diagnostic quality central priorities. BRICS economies represent a diverse but influential group where large patient populations, expanding tertiary care, national antimicrobial resistance strategies, and domestic diagnostic capacity development are increasing the relevance of rapid and scalable testing approaches. G7 countries generally demonstrate high diagnostic adoption, strong laboratory networks, and mature stewardship policies, with ongoing emphasis on reducing hospital-onset infections, improving turnaround times, and integrating diagnostics into digital care pathways. NATO countries include many health systems with advanced biodefense, emergency preparedness, and infection surveillance priorities, supporting demand for resilient diagnostic infrastructure that can address routine hospital infections as well as outbreak and preparedness scenarios. Across these groups, the strongest opportunities are linked to harmonized surveillance, procurement modernization, laboratory workforce development, diagnostic stewardship, and validated technologies that can be implemented across complex health systems.

Key Country Insights Across Major Healthcare Markets

The United States has a highly developed healthcare-associated infection surveillance environment, with strong emphasis on hospital reporting, antimicrobial stewardship, and rapid molecular diagnostics for high-risk care settings. Canada focuses on patient safety, antimicrobial resistance monitoring, and coordinated infection prevention practices across provincial healthcare systems. Mexico is expanding diagnostic capacity as hospital networks address infection control needs and antimicrobial resistance surveillance gaps. Brazil is a major Latin American market for hospital infection diagnostics due to its large healthcare system, reference laboratory infrastructure, and ongoing antimicrobial resistance initiatives. The United Kingdom emphasizes national surveillance, diagnostic stewardship, and infection prevention standards across hospitals, while Germany combines advanced laboratory infrastructure with strong microbiology and hospital quality systems. France continues to prioritize antimicrobial stewardship and infection surveillance, supported by structured healthcare quality programs, and Russia is advancing diagnostic capacity across large hospital networks while addressing regional variability in laboratory access. Italy and Spain maintain strong hospital microbiology capabilities and infection control programs, with continuing attention to surgical site infections, multidrug-resistant organisms, and C. difficile management. China is investing heavily in hospital modernization, molecular diagnostics, and antimicrobial resistance control as tertiary hospitals expand advanced testing capacity. India is strengthening infection prevention and diagnostic access through national antimicrobial resistance initiatives, growing private hospital networks, and increasing molecular testing adoption. Japan has a mature diagnostics environment with advanced hospital laboratories, aging-population care needs, and strong quality standards. Australia emphasizes national antimicrobial resistance surveillance, infection prevention guidelines, and high-quality laboratory networks, while South Korea combines advanced digital health infrastructure, hospital accreditation, and strong molecular diagnostics adoption. Across these countries, adoption patterns differ by reimbursement, laboratory maturity, workforce capacity, and regulatory pathways, but all share a common need for faster, accurate, and actionable diagnostics to reduce healthcare-associated infection risks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize solutions that align rapid diagnostics with infection prevention, antimicrobial stewardship, and hospital workflow efficiency. Product strategies should focus on clinically validated assays that deliver actionable pathogen identification and resistance insights within timeframes that influence treatment, isolation, and device-management decisions. Developers should strengthen interoperability with laboratory information systems, electronic health records, surveillance platforms, and antimicrobial stewardship dashboards to make diagnostic results usable at the point of care. Commercial teams should build evidence packages around patient outcomes, reduced time to optimal therapy, improved outbreak detection, lower unnecessary antimicrobial exposure, and operational efficiency rather than relying only on analytical performance claims. Organizations should also support diagnostic stewardship by providing clear use criteria, interpretation guidance, and education for clinicians, microbiologists, pharmacists, and infection preventionists. Regional strategies should account for differences in reimbursement, regulatory requirements, laboratory infrastructure, and workforce capacity, with scalable models for both high-throughput central laboratories and decentralized care settings. AI-enabled solutions should be deployed with transparent validation, cybersecurity protections, and clinical governance frameworks. Partnerships with hospitals, public health agencies, academic centers, and reference laboratories can accelerate real-world validation and adoption. Above all, industry leaders should position healthcare-associated infectious disease diagnostics as a patient safety and antimicrobial resistance mitigation tool, not merely as a laboratory product category.

Research Methodology

This executive summary is built on a structured secondary research approach using verified public health, clinical, regulatory, and industry-relevant sources. The analysis draws on evidence from hospital infection prevention guidelines, antimicrobial resistance action plans, healthcare quality reporting frameworks, peer-reviewed clinical literature, public health surveillance programs, regulatory publications, and laboratory medicine standards. The methodology emphasizes triangulation across multiple credible sources to identify consistent themes in diagnostic adoption, technology evolution, regional priorities, and healthcare system needs. Qualitative assessment was used to evaluate the role of culture-based diagnostics, molecular testing, immunoassays, sequencing, mass spectrometry, digital surveillance, and AI-enabled decision support in healthcare-associated infection management. Regional, group, and country insights were developed by reviewing healthcare infrastructure maturity, infection prevention priorities, antimicrobial resistance policies, laboratory capacity, and digital health readiness. The analysis deliberately excludes market sizing, market share, and forecasting, focusing instead on data-backed industry dynamics, clinical drivers, regulatory context, and strategic implications. Keywords and terminology were selected to align with healthcare-associated infection diagnostics, hospital-acquired infection testing, antimicrobial resistance diagnostics, infection prevention, molecular diagnostics, diagnostic stewardship, and clinical microbiology workflows while preserving accuracy and readability.

Conclusion

Healthcare-associated infectious disease diagnostics are entering a more integrated, data-driven, and clinically actionable era. The central challenge for healthcare systems is no longer only detecting pathogens, but doing so quickly enough to guide isolation, therapy, outbreak control, and antimicrobial stewardship decisions. Rapid molecular diagnostics, advanced microbiology workflows, sequencing, digital surveillance, and artificial intelligence are reshaping how hospitals identify and manage healthcare-associated infections. Regional momentum is strongest where infection prevention mandates, laboratory modernization, and antimicrobial resistance policies converge, but the need for reliable diagnostics is universal across advanced and emerging health systems. Future competitiveness will depend on clinical validation, workflow integration, affordability, interoperability, and evidence that diagnostic tools improve patient safety outcomes. Organizations that connect accurate testing with stewardship, surveillance, and real-time decision support will be best positioned to address the growing burden of healthcare-associated infections and multidrug-resistant organisms. In this environment, diagnostics serve as a strategic pillar of modern healthcare quality, enabling earlier intervention, better resource use, and stronger protection for patients, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method

  • 7.1. Introduction
  • 7.2. Immunoassays
    • 7.2.1. Chemiluminescent Immunoassay
    • 7.2.2. ELISA
    • 7.2.3. Lateral Flow Assays
  • 7.3. Microbiology
    • 7.3.1. Culture
      • 7.3.1.1. Aerobic Culture
      • 7.3.1.2. Anaerobic Culture
    • 7.3.2. Microscopy
    • 7.3.3. Sensitivity Testing
  • 7.4. Molecular Diagnostics
    • 7.4.1. Isothermal Amplification
    • 7.4.2. PCR
    • 7.4.3. Sequencing

8. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type

  • 8.1. Introduction
  • 8.2. Bacterial
    • 8.2.1. Clostridium Difficile
    • 8.2.2. Escherichia Coli
    • 8.2.3. Pseudomonas Aeruginosa
    • 8.2.4. Staphylococcus Aureus
  • 8.3. Fungal
    • 8.3.1. Aspergillus Species
    • 8.3.2. Candida Species
    • 8.3.3. Cryptococcus Neoformans
  • 8.4. Parasitic
    • 8.4.1. Malaria Parasites
    • 8.4.2. Toxoplasma Gondii
  • 8.5. Viral
    • 8.5.1. Coronavirus
    • 8.5.2. Influenza Virus
    • 8.5.3. Norovirus
    • 8.5.4. Respiratory Syncytial Virus

9. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Blood
    • 9.2.1. Serum
    • 9.2.2. Whole Blood
  • 9.3. Cerebrospinal Fluid
  • 9.4. Respiratory
    • 9.4.1. Bronchoalveolar Lavage
    • 9.4.2. Nasopharyngeal Swabs
    • 9.4.3. Sputum
  • 9.5. Urine
    • 9.5.1. Catheterized Urine
    • 9.5.2. Midstream Urine
  • 9.6. Wound Swabs
    • 9.6.1. Deep Tissue Samples
    • 9.6.2. Surface Swabs

10. Healthcare-associated Infectious Disease Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Independent Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Hospitals
    • 10.3.1. Clinical Pathology Laboratories
    • 10.3.2. Microbiology Laboratories
  • 10.4. Point Of Care
    • 10.4.1. Clinics
    • 10.4.2. Emergency Departments
    • 10.4.3. Long Term Care Facilities

11. Healthcare-associated Infectious Disease Diagnostics Market, by Application

  • 11.1. Introduction
  • 11.2. Screening
  • 11.3. Diagnosis
  • 11.4. Monitoring
  • 11.5. Surveillance

12. Healthcare-associated Infectious Disease Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Healthcare-associated Infectious Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Healthcare-associated Infectious Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Accelerate Diagnostics Inc
  • 16.3. Agilent Technologies Inc
  • 16.4. Bio-Rad Laboratories Inc
  • 16.5. bioMerieux SA
  • 16.6. Co-Diagnostics Inc
  • 16.7. Danaher Corporation
  • 16.8. DiaSorin S.p.A.
  • 16.9. F. Hoffmann-La Roche Ltd
  • 16.10. Genetic Signatures Ltd
  • 16.11. Grifols S.A.
  • 16.12. Hologic Inc
  • 16.13. Illumina Inc
  • 16.14. Labcorp Holdings Inc
  • 16.15. Luminex Corporation
  • 16.16. Merck KGaA
  • 16.17. Meridian Bioscience Inc
  • 16.18. Natera Inc
  • 16.19. OpGen Inc
  • 16.20. OraSure Technologies Inc
  • 16.21. QIAGEN N.V.
  • 16.22. QuidelOrtho Corporation
  • 16.23. Revvity Inc
  • 16.24. SD Biosensor Inc
  • 16.25. Seegene Inc
  • 16.26. Siemens Healthineers AG
  • 16.27. Sysmex Corporation
  • 16.28. Thermo Fisher Scientific Inc
  • 16.29. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LATERAL FLOW ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LATERAL FLOW ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LATERAL FLOW ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AEROBIC CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AEROBIC CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AEROBIC CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANAEROBIC CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANAEROBIC CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANAEROBIC CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SENSITIVITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SENSITIVITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SENSITIVITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLOSTRIDIUM DIFFICILE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLOSTRIDIUM DIFFICILE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLOSTRIDIUM DIFFICILE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASPERGILLUS SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ASPERGILLUS SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASPERGILLUS SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANDIDA SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANDIDA SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANDIDA SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRYPTOCOCCUS NEOFORMANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRYPTOCOCCUS NEOFORMANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRYPTOCOCCUS NEOFORMANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALARIA PARASITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MALARIA PARASITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALARIA PARASITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TOXOPLASMA GONDII MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TOXOPLASMA GONDII MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TOXOPLASMA GONDII MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CORONAVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORONAVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CORONAVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NOROVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NOROVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NOROVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHOALVEOLAR LAVAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHOALVEOLAR LAVAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHOALVEOLAR LAVAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CATHETERIZED URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CATHETERIZED URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CATHETERIZED URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MIDSTREAM URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MIDSTREAM URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MIDSTREAM URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL WOUND SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL WOUND SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL WOUND SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DEEP TISSUE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DEEP TISSUE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DEEP TISSUE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SURFACE SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL SURFACE SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL SURFACE SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CLINICAL PATHOLOGY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CLINICAL PATHOLOGY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CLINICAL PATHOLOGY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL MICROBIOLOGY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL MICROBIOLOGY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL MICROBIOLOGY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL EMERGENCY DEPARTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL EMERGENCY DEPARTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL EMERGENCY DEPARTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 322. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)